PMID- 29943375
OWN - NLM
STAT- MEDLINE
DCOM- 20190516
LR  - 20190516
IS  - 1179-1950 (Electronic)
IS  - 0012-6667 (Linking)
VI  - 78
IP  - 11
DP  - 2018 Jul
TI  - Regorafenib: A Review in Metastatic Colorectal Cancer.
PG  - 1133-1144
LID - 10.1007/s40265-018-0938-y [doi]
AB  - Regorafenib (Stivarga((R))) is an oral small-molecule multiple kinase inhibitor. It 
      is indicated worldwide for patients with metastatic colorectal cancer (mCRC). In 
      the EU and USA it is indicated for patients with mCRC who have been previously 
      treated with, or are not considered candidates for available therapies, including 
      fluoropyrimidine-based chemotherapy, an anti-VEGF therapy and, if RAS wild-type, 
      an anti-EGFR therapy. In Japan, it is indicated for the treatment of 
      unresectable, advanced/recurrent CRC. The addition of regorafenib to best 
      supportive care prolonged median overall survival (OS; by up to 2.5 months) and 
      progression-free survival (PFS; by up to 1.5 months) relative to the addition of 
      placebo in double-blind phase 3 studies (CORRECT and CONCUR) in patients with 
      mCRC who had progressed after failure of standard therapy. Health-related quality 
      of life was not adversely affected with regorafenib relative to placebo. A large 
      open-label phase 3 study (CONSIGN) and several large real-world studies supported 
      the efficacy of regorafenib in this setting. Regorafenib had a generally 
      manageable tolerability profile, which was consistent with the profile of a 
      typical small-molecule multiple kinase inhibitor. Treatment-related adverse 
      events (AEs), mostly of mild or moderate severity, were reported in the majority 
      of patients receiving regorafenib, with dermatological toxicities and liver 
      enzyme elevations among the most common AEs. Although identification of 
      biomarkers/parameters predicting efficacy outcomes with regorafenib will help to 
      individualize therapy, current evidence indicates that regorafenib is a valuable 
      treatment option for patients with refractory mCRC who have a very poor 
      prognosis.
FAU - Dhillon, Sohita
AU  - Dhillon S
AD  - Springer, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. 
      demail@springer.com.
LA  - eng
PT  - Journal Article
PT  - Review
PL  - New Zealand
TA  - Drugs
JT  - Drugs
JID - 7600076
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Phenylurea Compounds)
RN  - 0 (Pyridines)
RN  - 24T2A1DOYB (regorafenib)
SB  - IM
MH  - Antineoplastic Agents/administration & 
      dosage/pharmacokinetics/pharmacology/*therapeutic use
MH  - Clinical Trials, Phase III as Topic
MH  - Colorectal Neoplasms/*drug therapy/pathology
MH  - Dose-Response Relationship, Drug
MH  - Humans
MH  - Neoplasm Metastasis
MH  - Phenylurea Compounds/administration & 
      dosage/pharmacokinetics/pharmacology/*therapeutic use
MH  - Pyridines/administration & dosage/pharmacokinetics/pharmacology/*therapeutic use
MH  - Quality of Life
EDAT- 2018/06/27 06:00
MHDA- 2019/05/17 06:00
CRDT- 2018/06/27 06:00
PHST- 2018/06/27 06:00 [pubmed]
PHST- 2019/05/17 06:00 [medline]
PHST- 2018/06/27 06:00 [entrez]
AID - 10.1007/s40265-018-0938-y [pii]
AID - 10.1007/s40265-018-0938-y [doi]
PST - ppublish
SO  - Drugs. 2018 Jul;78(11):1133-1144. doi: 10.1007/s40265-018-0938-y.